CDK1 and neoplasm: [189] showed that in non‐small cell lung cancer, fargesin could interfere with tumor glycolysis by targeting the key rate‐limiting enzyme PKM2, inhibiting the production of lactate, and inhibiting the lactylation of H3 histone, accompanied by the downregulated expression of proliferation‐associated proteins CDK1, CCND1, and BCL2 and upregulated expression of the apoptosis‐associated protein BAX, thereby inhibiting tumor cell proliferation and migration and exerting antitumor effects.